The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations

References

• 2014 National Diabetes Statistics Report. Centers for Disease Control. 2014 [ cited Jul 26]. Available from: http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html
   Google Scholar
• Marshall MC Jr. Diabetes in African Americans. Postgrad Med J. 2005;81:734–740.
   PubMed Web of Science ®Google Scholar
• Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. Curr Diab Rep. 2013;13:814–823.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics – 2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–e360.
   PubMed Web of Science ®Google Scholar
• Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. 2015;314:1021–1029.
   PubMed Web of Science ®Google Scholar
• IDF Diabetes Atlas. 7th Edition. International Diabetes Federation, 2015. 2016 [ cited Feb 18]. Available from: http://www.diabetesatlas.org/
   Google Scholar
• Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–814.
   PubMed Web of Science ®Google Scholar
• Fox CS, Pencina MJ, Wilson PW, et al. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study. Diabetes Care. 2008;31:1582–1584.
   PubMed Web of Science ®Google Scholar
• Golden SH, Brown A, Cauley JA, et al. Health disparities in endocrine disorders: biological, clinical, and nonclinical factors – an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2012;97:E1579–E1639.
   PubMed Web of Science ®Google Scholar
• Kuzawa CW, Sweet E. Epigenetics and the embodiment of race: developmental origins of US racial disparities in cardiovascular health. Am J Hum Biol. 2009;21:2–15.
   PubMed Web of Science ®Google Scholar
• Kirk JK, D’Agostino RB Jr., Bell RA, et al. Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care. 2006;29:2130–2136.
   PubMed Web of Science ®Google Scholar
• Kountz D. Special considerations of care and risk management for African American patients with type 2 diabetes mellitus. J Natl Med Assoc. 2012;104:265–273.
   PubMed Web of Science ®Google Scholar
• Banerji MA. Diabetes in African Americans: unique pathophysiologic features. Curr Diab Rep. 2004;4:219–223.
   PubMedGoogle Scholar
• Nwankwo T, Yoon SS, Burt V, et al. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011–2012. NCHS Data Brief. 2013;133:1–8.
   PubMedGoogle Scholar
• Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56:780–800.
   PubMed Web of Science ®Google Scholar
• Ogedegbe G, Shah NR, Phillips C, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitor-based treatment on cardiovascular outcomes in hypertensive blacks versus whites. J Am Coll Cardiol. 2015;66:1224–1233.
   PubMed Web of Science ®Google Scholar
• Gerber LM, Mann SJ, McDonald MV, et al. Diuretic use in black patients with uncontrolled hypertension. Am J Hypertens. 2013;26:174–179.
   PubMed Web of Science ®Google Scholar
• Harman J, Walker ER, Charbonneau V, et al. Treatment of hypertension among African Americans: the Jackson Heart Study. J Clin Hypertens (Greenwich). 2013;15:367–374.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–520.
   PubMed Web of Science ®Google Scholar
• Muntner P, Newsome B, Kramer H, et al. Racial differences in the incidence of chronic kidney disease. Clin J Am Soc Nephrol. 2012;7:101–107.
   PubMed Web of Science ®Google Scholar
• Delanaye P, Mariat C, Maillard N, et al. Are the creatinine-based equations accurate to estimate glomerular filtration rate in African American populations? Clin J Am Soc Nephrol. 2011;6:906–912.
   PubMed Web of Science ®Google Scholar
• Peralta CA, Lin F, Shlipak MG, et al. Race differences in prevalence of chronic kidney disease among young adults using creatinine-based glomerular filtration rate-estimating equations. Nephrol Dial Transplant. 2010;25:3934–3939.
   PubMed Web of Science ®Google Scholar
• Wright JT Jr., Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–2431.
   PubMed Web of Science ®Google Scholar
• Norris K, Bourgoigne J, Gassman J, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis. 2006;48:739–751.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Nasser SA. Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31:913–923.
   PubMed Web of Science ®Google Scholar
• Hoppe C, Kerr D. Minority underrepresentation in cardiovascular outcome trials for type 2 diabetes. Lancet Diabetes Endocrinol. 2017;5:13.
   PubMed Web of Science ®Google Scholar
• Thrasher J, Kountz DS, Crowe S, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: pooled analysis from eight phase III trials. Postgrad Med. 2015;127:419–428.
   PubMed Web of Science ®Google Scholar
• Gavin JR 3rd, Davies MJ, Davies M, et al. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31:1693–1702.
   PubMed Web of Science ®Google Scholar
• Prescribing information: INVOKANA® (canagliflozin) tablets, for oral use. Janssen Pharmaceuticals, Inc. 2016 May [cited Jun 20]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204042s015s019lbl.pdf
   Google Scholar
• Prescribing information: JARDIANCE® (empagliflozin) tablets, for oral use. Boehringer Ingelheim Pharmaceuticals, Inc. 2016 Jul [cited Aug 9]. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf
   Google Scholar
• Prescribing information: FARXIGA® (dapagliflozin) tablets, for oral use. AstraZeneca Pharmaceuticals LP. 2016 Jun [cited Jun 20]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202293s009lbl.pdf
   Google Scholar
• Ejiogu N, Norbeck JH, Mason MA, et al. Recruitment and retention strategies for minority or poor clinical research participants: lessons from the Healthy Aging in Neighborhoods of Diversity across the Life Span study. Gerontologist. 2011;51(Suppl 1):S33–45.
   PubMed Web of Science ®Google Scholar
• Mount DL, Davis C, Kennedy B, et al. Factors influencing enrollment of African Americans in the Look AHEAD trial. Clin Trials. 2012;9:80–89.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Seman L, Salsali A. Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus. Endocr Pract. 2016;22(Suppl 2):80–81 (Abstract 292).
   Google Scholar
• Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008;14:782–790.
   PubMedGoogle Scholar
• Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427–3434.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5–14.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Defronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes. 2013;62:3324–3328.
   PubMed Web of Science ®Google Scholar
• Zhang L, Feng Y, List J, et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010;12:510–516.
   PubMed Web of Science ®Google Scholar
• Yang XP, Lai D, Zhong XY, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol. 2014;70:1149–1158.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang L, Wu B, et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30:204–221.
   PubMed Web of Science ®Google Scholar
• Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984–993.
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. U.S. Food and Drug Administration. 2015. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm
   Google Scholar
• Tang H, Li D, Wang T, et al. Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2016;39:e123–124.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638–1642.
   PubMed Web of Science ®Google Scholar
• Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol. 2014;13:102.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:1801–1802.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. The EMPA-REG study: what has it told us? A diabetologist’s perspective. J Diabetes Complications. 2016;30:1–2.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: a critical analysis. Diabetes Metab. 2016;42:71–76.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39:717–725.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics. Diabetes Metab. 2016;42:224–233.
   PubMed Web of Science ®Google Scholar
• Tikkanen I, Chilton R, Johansen OE. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension. Curr Opin Nephrol Hypertens. 2016;25:81–86.
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ, De Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853–862.
   PubMed Web of Science ®Google Scholar
• Kimura G. Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis. J Am Soc Hypertens. 2016;10:271–278.
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Stenlof K, Leiter LA, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58:1183–1187.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care. 2016;39:1108–1114.
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115–1122.
   PubMed Web of Science ®Google Scholar
• CANVAS – CANagliflozin cardioVascular Assessment Study (CANVAS). [ cited Sep 8]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01032629
   Google Scholar
• Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). DECLARE-TIMI 58. [ cited Sep 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT01730534
   Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Optimising the analysis strategy for the CANVAS Program – a pre-specified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab. 2017 Feb 28. doi:10.1111/dom.12924 [Epub ahead of print]
   Google Scholar
• Cardiovascular outcomes following ertugliflozin treatment in type 2 diabetes mellitus participants with vascular disease, the VERTIS CV study (MK-8835-004). Ertugliflozin Cardiovascular Outcomes Trial. [ cited Feb 16]. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT01986881
   Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
   PubMed Web of Science ®Google Scholar
• A study of the effects of canagliflozin (JNJ-28431754) on renal endpoints in adult participants with type 2 diabetes mellitus (CANVAS-R). CANVAS-R. [ cited Sep 8]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01989754
   Google Scholar
• Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–830.
   PubMed Web of Science ®Google Scholar
• Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns – NHANES 2007–2012. BMJ Open Diabetes Res Care. 2016;4:e000154.
   PubMed Web of Science ®Google Scholar
• Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24:302–308.
   PubMed Web of Science ®Google Scholar
• Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int. 1983;23:647–655.
   PubMed Web of Science ®Google Scholar
• Fioretto P, Zambon A, Rossato M, et al. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39(Suppl 2):S165–S71.
   PubMed Web of Science ®Google Scholar
• Jerums G, Premaratne E, Panagiotopoulos S, et al. The clinical significance of hyperfiltration in diabetes. Diabetologia. 2010;53:2093–2104.
   PubMed Web of Science ®Google Scholar
• Gaspari F, Ruggenenti P, Porrini E, et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int. 2013;84:164–173.
   PubMed Web of Science ®Google Scholar
• Škrtić M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens. 2015;24:96–103.
   PubMed Web of Science ®Google Scholar
• Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014;306:F194–F204.
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–597.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine M, Vijapurkar U, et al. Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med Res Opin. 2015;31:2219–2231.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Fioretto P, Johnsson K, et al. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016;29:391–400.
   PubMed Web of Science ®Google Scholar
• Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369–384.
   PubMed Web of Science ®Google Scholar
• Evaluation of the effects of canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy (CREDENCE). CREDENCE. [ cited Sep 8]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02065791
   Google Scholar
• Scheen AJ, Delanaye P. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab. 2017 Jan 30. doi:10.1016/j.diabet.2016.12.010. [Epub ahead of print]
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Fioretto P, Mansfield TA, Ptaszynska A, et al. Long-term safety of dapagliflozin in older patients with type 2 diabetes mellitus: a pooled analysis of phase IIb/III studies. Drugs Aging. 2016;33:511–522.
   PubMed Web of Science ®Google Scholar
• Parveen R, Agarwal NB, Kaushal N, et al. Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. Expert Opin Pharmacother. 2016;17:105–115.
   PubMed Web of Science ®Google Scholar
• Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016;38:1299–1313.
   PubMed Web of Science ®Google Scholar
• Singh JS, Fathi A, Vickneson K, et al. Research into the effect of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol. 2016;15:97.
   PubMed Web of Science ®Google Scholar
• Kenney WL, Chiu P. Influence of age on thirst and fluid intake. Med Sci Sports Exerc. 2001;33:1524–1532.
   PubMed Web of Science ®Google Scholar
• Yavin Y, Mansfield TA, Ptaszynska A, et al. Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Ther. 2016;7:125–137.
   PubMed Web of Science ®Google Scholar